Search Results

Lifecore Biomedical, Inc. announced it has reached a cooperation agreement with 22NW, LP, which provides for the addition of Humberto Antunes, Jason Aryeh, Paul Johnson and Matthew Korenberg to the Board of Directors of the Company effective immediately following the 2023 Annual Meeting of Stockholders.

Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization, announced certain incremental liquidity measures and housekeeping matters related to divested businesses through a series of 8-K filings over the past week.

Lifecore Biomedical, Inc. announced that Lifecore has granted a restricted stock unit award with respect to 525,000 shares of its common stock and a performance stock unit award for up to 1,500,000 shares of its common stock to Paul Josephs, Lifecore’s newly hired President and Chief Executive Officer.

Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provided a business update, including certain select preliminary financial data, outlook for full year fiscal 2024, the status of its development portfolio and pipeline and capacity expansion.

Lifecore Biomedical, Inc. announced today that it has filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023 (“FY23”) with the United States Securities and Exchange Commission (the “SEC”).

Lifecore Biomedical, Inc. today announced that its Board of Directors unanimously approved the conclusion of its review of strategic alternatives that was initiated in March 2023, and, concurrently therewith, announced several strategic updates related to its operations on a stand-alone basis.